![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Impact of Ribavirin on Real World Adherence and Discontinuation
Rates in HCV Patients Treated with Sofosbuvir + Simeprevir
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
David R Walker1, Timothy R Juday1, Shivaji R Manthena2, Yonghua Jing2, Vipan Sood1
1Global Health Economics & Outcomes Research, AbbVie, North Chicago, IL, USA; 2Health Economics & Outcomes Research, AbbVie, North Chicago, IL, USA
![EASL1.gif](../images/051815/051815-5/EASL1.gif)
![EASL2.gif](../images/051815/051815-5/EASL2.gif)
![EASL3.gif](../images/051815/051815-5/EASL3.gif)
![EASL4.gif](../images/051815/051815-5/EASL4.gif)
![EASL5.gif](../images/051815/051815-5/EASL5.gif)
![EASL6.gif](../images/051815/051815-5/EASL6.gif)
![EASL7.gif](../images/051815/051815-5/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|